| __timestamp | TG Therapeutics, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 24518692 | 59644696 |
| Thursday, January 1, 2015 | 19886580 | 79541000 |
| Friday, January 1, 2016 | 12631689 | 98015000 |
| Sunday, January 1, 2017 | 21977998 | 103958000 |
| Monday, January 1, 2018 | 20759000 | 103654000 |
| Tuesday, January 1, 2019 | 20838000 | 128951000 |
| Wednesday, January 1, 2020 | 121812000 | 135799000 |
| Friday, January 1, 2021 | 152137000 | 149883000 |
| Saturday, January 1, 2022 | 83231000 | 220206000 |
| Sunday, January 1, 2023 | 122706000 | 265542000 |
Unleashing insights
In the dynamic world of biotechnology, understanding financial trends is crucial. Over the past decade, TG Therapeutics, Inc. and Travere Therapeutics, Inc. have shown distinct patterns in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Travere Therapeutics consistently outpaced TG Therapeutics, with SG&A expenses peaking at approximately 265% higher in 2023 compared to 2014. TG Therapeutics, on the other hand, saw a significant increase in 2020, with expenses rising by nearly 500% from 2014, reflecting strategic investments in growth. This financial trajectory highlights the contrasting strategies of these two companies in managing operational costs. As the biotech sector continues to evolve, such insights are invaluable for investors and stakeholders aiming to navigate the complexities of corporate financial health.
Breaking Down SG&A Expenses: Zoetis Inc. vs TG Therapeutics, Inc.
Breaking Down SG&A Expenses: Summit Therapeutics Inc. vs TG Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Travere Therapeutics, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs TG Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Cytokinetics, Incorporated or TG Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing TG Therapeutics, Inc. and Veracyte, Inc.
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Mesoblast Limited and Travere Therapeutics, Inc.
Breaking Down SG&A Expenses: MannKind Corporation vs Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.